OraSure (OSUR) Q2 FY26 earnings call

OraSure delivered a strong Q2 FY26, surpassing revenue guidance and expanding gross margins, driven by sequential growth in both Diagnostic Products and Sample Management Solutions. While the InteliQuick CT/NG test faces a regulatory delay, the company remains confident in its pipeline, including recent FDA clearances for Colli-Pee Dx and OraQuick Ebola 2.0, and is focused on achieving operating cash flow breakeven by early 2027 through disciplined execution and strategic launches.